A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy


About this study

The purpose of this study is to assess the safety and effectiveness of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female subjects between 15 and 75 years of age, inclusive.
  • Primary diagnosis of narcolepsy with cataplexy.
  • Willing and able to comply with the study requirements.

Exclusion Criteria:

  • Individuals < 15 and > 75 years of age.
  • Other clinically significant conditions potentially causing EDS.
  • Clinically significant psychiatric disorders
    • *NOTE:  Mayo Clinic will only recruit participants 18 years of age and older. This was approved by the sponsor.

Eligibility last updated 11/12/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Lois Krahn, M.D.

Open for enrollment

Contact information:

Goddess White

(480) 574-2261


More information


Publications are currently not available

Mayo Clinic Footer